The goal of the Lymphoma and Hodgkin Disease Program is to gain a better understanding of the biology underlying lymphoid neoplasms and to apply this knowledge to improve the diagnosis and treatment of these disorders. In working toward this goal, we have a broad research program with major themes of lymphoma pathogenesis, clinical pathological relationships, novel therapeutics and clinical trials. Our resources include a large clinical database of >10,000 lymphoma and 5,000 Hodgkin lymphoma over a follow-up period of 40 years and a tissue bank containing 5,500 fresh-frozen specimens. The 27 members within our program represent 11 departments within the School of Medicine and the School of Engineering. Investigators in the Lymphoma and Hodgkin Disease Program have 16 grants, including 1 P01;1 SCOR;1 P20;4 R01;1 T32;3 K and other peer-reviewed awards. The annual direct NCI support in 2008 totaled $3.5 million. Our program has emphasized translational research to the clinic in diagnostics and novel therapeutics and from the clinic to the laboratory in the correlation of studies on tissues matched with clinical events. During the past five years, over 300 publications have appeared in peer-reviewed journals. Laboratory-based projects are focused on the detection of signaling pathways in individual cells;lymphomagenesis, with attention to the MYC oncogene and the immune response to hepatitis C;development of novel diagnostics, including new gene discovery and new monoclonal antibodies directed against these genes;and model systems for a new method of therapeutic vaccination. Our clinical studies have a focus on immunotherapy and novel combined modality treatments and concepts from our group have moved into influential Phase III clinical trials in the Eastern Cooperative Oncology Group (ECOG).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-08
Application #
8685161
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
8
Fiscal Year
2014
Total Cost
$52,923
Indirect Cost
$38,624
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Denny, Sarah K; Yang, Dian; Chuang, Chen-Hua et al. (2016) Nfib Promotes Metastasis through a Widespread Increase in Chromatin Accessibility. Cell 166:328-42
Li, Jian; Pfeffer, Suzanne R (2016) Lysosomal membrane glycoproteins bind cholesterol and contribute to lysosomal cholesterol export. Elife 5:
Chuang, Jody C; Shrager, Joseph B; Wakelee, Heather A et al. (2016) Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy. Clin Ther 38:1567-76
Wanigatunga, Amal A; Sourdet, Sandrine S; LaMonte, Michael J et al. (2016) Physical impairment and body weight history in postmenopausal women: the Women's Health Initiative. Public Health Nutr 19:3169-3177
Zanganeh, Saeid; Hutter, Gregor; Spitler, Ryan et al. (2016) Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol 11:986-994
Hiniker, Susan M; Reddy, Sunil A; Maecker, Holden T et al. (2016) A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. Int J Radiat Oncol Biol Phys 96:578-88
Grüner, Barbara M; Schulze, Christopher J; Yang, Dian et al. (2016) An in vivo multiplexed small-molecule screening platform. Nat Methods 13:883-9
Chen, Frank W; Sundaram, Vandana; Chew, Thomas A et al. (2016) Advanced Stage Colorectal Cancer in Persons Younger Than 50 Years not Associated With Longer Duration of Symptoms or Time to Diagnosis. Clin Gastroenterol Hepatol :
Zhu, Gefei Alex; Lira, Ruth; Colevas, Alexander Dimitrios (2016) Discordance in routine second opinion pathology review of head and neck oncology specimens: A single-center five year retrospective review. Oral Oncol 53:36-41
Brady, Jennifer J; Chuang, Chen-Hua; Greenside, Peyton G et al. (2016) An Arntl2-Driven Secretome Enables Lung Adenocarcinoma Metastatic Self-Sufficiency. Cancer Cell 29:697-710

Showing the most recent 10 out of 278 publications